Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Editorial: HBV-the naked truth? Authors' reply.

Jiang B, Peiffer KH, Hildt E.

Aliment Pharmacol Ther. 2019 Oct;50(8):964-965. doi: 10.1111/apt.15452. No abstract available.

PMID:
31591771
2.

Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.

Graf C, Mücke MM, Dultz G, Peiffer KH, Kubesch A, Ingiliz P, Zeuzem S, Herrmann E, Vermehren J.

Clin Infect Dis. 2019 Sep 12. pii: ciz696. doi: 10.1093/cid/ciz696. [Epub ahead of print]

PMID:
31513710
3.

Formation of semi-enveloped particles as a unique feature of a hepatitis B virus PreS1 deletion mutant.

Jiang B, Wu Q, Kuhnhenn L, Akhras S, Spengler C, Boller K, Peiffer KH, Hildt E.

Aliment Pharmacol Ther. 2019 Oct;50(8):940-954. doi: 10.1111/apt.15381. Epub 2019 Jun 25.

PMID:
31240738
4.

Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras.

Peiffer KH, Kuhnhenn L, Stelzl E, Dietz J, Susser S, Tal AO, Finkelmeier F, Zuckerman E, Cornberg M, Barak M, Piazzolla V, Mangia A, Zeuzem S, Kessler HH, Vermehren J, Sarrazin C.

J Clin Microbiol. 2019 Jun 25;57(7). pii: e00060-19. doi: 10.1128/JCM.00060-19. Print 2019 Jul.

PMID:
31043467
5.

Absence of HBV Reactivation in Patients With Resolved HBV Infection Following DAA Therapy for Hepatitis C: A 1-Year Follow-up Study.

Mücke MM, Mücke VT, Peiffer KH, Sarrazin C, Zeuzem S, Berger A, Vermehren J.

Open Forum Infect Dis. 2018 Dec 15;6(1):ofy340. doi: 10.1093/ofid/ofy340. eCollection 2019 Jan.

6.

Serum sphingolipid levels associate with upcoming virologic events and HBV genotype D in a cohort of patients with HBeAg-negative HBV infection.

Mücke VT, Jakobi K, Knop V, Thomas D, Mücke MM, Peiffer KH, Zeuzem S, Sarrazin C, Pfeilschifter J, Grammatikos G.

PLoS One. 2018 Nov 15;13(11):e0207293. doi: 10.1371/journal.pone.0207293. eCollection 2018.

7.

Circulating hypoxia marker carbonic anhydrase IX (CA9) in patients with hepatocellular carcinoma and patients with cirrhosis.

Finkelmeier F, Canli Ö, Peiffer KH, Walter D, Tal A, Koch C, Pession U, Vermehren J, Trojan J, Zeuzem S, Piiper A, Greten FR, Grammatikos G, Waidmann O.

PLoS One. 2018 Jul 16;13(7):e0200855. doi: 10.1371/journal.pone.0200855. eCollection 2018.

8.

Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals.

Finkelmeier F, Dultz G, Peiffer KH, Kronenberger B, Krauss F, Zeuzem S, Sarrazin C, Vermehren J, Waidmann O.

Liver Cancer. 2018 May;7(2):190-204. doi: 10.1159/000486812. Epub 2018 Mar 1.

9.

Editorial: HBsAg serum levels in HBeAg-negative chronic HBV infection-is it a matter of genotype? Authors' reply.

Kuhnhenn L, Jiang B, Kubesch A, Zeuzem S, Sarrazin C, Hildt E, Peiffer KH.

Aliment Pharmacol Ther. 2018 Jul;48(1):103-104. doi: 10.1111/apt.14793. No abstract available.

PMID:
29882986
10.

Impact of HBV genotype and mutations on HBV DNA and qHBsAg levels in patients with HBeAg-negative chronic HBV infection.

Kuhnhenn L, Jiang B, Kubesch A, Vermehren J, Knop V, Susser S, Dietz J, Carra G, Finkelmeier F, Grammatikos G, Zeuzem S, Sarrazin C, Hildt E, Peiffer KH.

Aliment Pharmacol Ther. 2018 Jun;47(11):1523-1535. doi: 10.1111/apt.14636. Epub 2018 Apr 10.

PMID:
29637585
11.

Interferon-free treatment choice according to baseline RASs leads to high SVR rates in HCV genotype 1 infected patients.

Peiffer KH, Vermehren J, Kuhnhenn L, Susser S, Dietz J, Finkelmeier F, Weiler N, Welzel T, Grammatikos G, Zeuzem S, Sarrazin C.

J Infect Chemother. 2018 Jul;24(7):524-530. doi: 10.1016/j.jiac.2018.02.008. Epub 2018 Apr 5.

PMID:
29628383
12.

Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients.

Peiffer KH, Kuhnhenn L, Jiang B, Mondorf A, Vermehren J, Knop V, Susser S, Walter D, Dietz J, Carra G, Finkelmeier F, Zeuzem S, Sarrazin C, Hildt E.

J Infect Dis. 2018 Jun 5;218(1):114-123. doi: 10.1093/infdis/jiy119.

PMID:
29528436
13.

Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.

Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Müllhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Hüppe D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, von Hahn T, Berg T, Zeuzem S, Sarrazin C; European HCV Resistance Study Group.

Gastroenterology. 2018 Mar;154(4):976-988.e4. doi: 10.1053/j.gastro.2017.11.007. Epub 2017 Nov 13.

PMID:
29146520
14.

Diagnostic Yield and Outcomes of Computed Tomography of the Head in Critically Ill Nontrauma Patients.

Finkelmeier F, Walter S, Peiffer KH, Cremer A, Tal A, Vogl T, Zeuzem S, Fichtlscherer S, Friedrich-Rust M, Bojunga J, Farnik H.

J Intensive Care Med. 2017 Jan 1:885066617720901. doi: 10.1177/0885066617720901. [Epub ahead of print]

PMID:
28718341
15.

No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort.

Mücke VT, Mücke MM, Peiffer KH, Weiler N, Welzel TM, Sarrazin C, Zeuzem S, Berger A, Vermehren J.

Aliment Pharmacol Ther. 2017 Aug;46(4):432-439. doi: 10.1111/apt.14177. Epub 2017 Jun 19.

16.

Comparative characterization of hepatitis B virus surface antigen derived from different hepatitis B virus genotypes.

Hassemer M, Finkernagel M, Peiffer KH, Glebe D, Akhras S, Reuter A, Scheiblauer H, Sommer L, Chudy M, Nübling CM, Hildt E.

Virology. 2017 Feb;502:1-12. doi: 10.1016/j.virol.2016.12.003. Epub 2016 Dec 9.

17.

The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection.

Vermehren J, Peiffer KH, Welsch C, Grammatikos G, Welker MW, Weiler N, Zeuzem S, Welzel TM, Sarrazin C.

Aliment Pharmacol Ther. 2016 Oct;44(8):856-65. doi: 10.1111/apt.13769. Epub 2016 Aug 23.

18.

Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy.

Dietz J, Rupp D, Susser S, Vermehren J, Peiffer KH, Filmann N, Bon D, Kuntzen T, Mauss S, Grammatikos G, Perner D, Berkowski C, Herrmann E, Zeuzem S, Bartenschlager R, Sarrazin C.

PLoS One. 2016 Jun 9;11(6):e0156731. doi: 10.1371/journal.pone.0156731. eCollection 2016.

19.

Reply.

Peiffer KH, Sommer L, Zeuzem S, Sarrazin C.

Hepatology. 2016 Oct;64(4):1378-9. doi: 10.1002/hep.28536. Epub 2016 Apr 15. No abstract available.

PMID:
26946328
20.

[New methods for endoscopic hemostasis: focus on non-variceal gastrointestinal bleeding].

Albert JG, Peiffer KH.

Z Gastroenterol. 2016 Mar;54(3):250-5. doi: 10.1055/s-0035-1566987. Epub 2016 Feb 19. Review. German.

PMID:
26894683
21.

Formalizing the Austrian Procedure Catalogue: A 4-step methodological analysis approach.

Neururer SB, Lasierra N, Peiffer KP, Fensel D.

J Biomed Inform. 2016 Apr;60:1-13. doi: 10.1016/j.jbi.2015.12.018. Epub 2015 Dec 30.

22.

Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3.

Peiffer KH, Sommer L, Susser S, Vermehren J, Herrmann E, Döring M, Dietz J, Perner D, Berkowski C, Zeuzem S, Sarrazin C.

Hepatology. 2016 Jan;63(1):63-73. doi: 10.1002/hep.28255. Epub 2015 Nov 25.

PMID:
26406534
23.

Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders.

Fülöp B, Biermer M, Cornberg M, Wedemeyer H, Port K, Heyne R, Zeuzem S, Peiffer KH, Welzel T, Herber A, Buggisch P, Moser C, Stoll S, Alshuth U, Berg T.

Liver Int. 2015 Oct;35(10):2275-84. doi: 10.1111/liv.12832. Epub 2015 Apr 20.

PMID:
25801095
24.

Intracellular accumulation of subviral HBsAg particles and diminished Nrf2 activation in HBV genotype G expressing cells lead to an increased ROI level.

Peiffer KH, Akhras S, Himmelsbach K, Hassemer M, Finkernagel M, Carra G, Nuebling M, Chudy M, Niekamp H, Glebe D, Sarrazin C, Zeuzem S, Hildt E.

J Hepatol. 2015 Apr;62(4):791-8. doi: 10.1016/j.jhep.2014.11.028. Epub 2014 Nov 28.

PMID:
25445396
25.

The importance of HCV RNA measurement for tailoring treatment duration.

Peiffer KH, Sarrazin C.

Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S323-31. doi: 10.1016/j.dld.2013.07.007. Review.

PMID:
24091111
26.

Iron deficiency anaemia and cataracts in a patient with haemochromatosis.

Peiffer KH, Niemeyer M, Buslau A, Kohnen T, Muckenthaler MU, Zeuzem S, Sarrazin C.

Gut. 2014 Apr;63(4):686, 698. doi: 10.1136/gutjnl-2013-305049. Epub 2013 Jul 18. No abstract available.

PMID:
23868327
27.

Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection.

Vermehren J, Susser S, Berger A, Perner D, Peiffer KH, Allwinn R, Zeuzem S, Sarrazin C.

J Clin Virol. 2012 Sep;55(1):17-22. doi: 10.1016/j.jcv.2012.05.008. Epub 2012 Jun 13.

PMID:
22698697
28.
29.

Brain death and organ procurement.

Peiffer KM.

Am J Nurs. 2007 Mar;107(3):58-67; quiz 68. Review.

PMID:
17314560
30.

Structure of calcium 2,6-difluorobenzoate dihydrate.

Karipides A, White C, Peiffer K.

Acta Crystallogr C. 1992 Jun 15;48 ( Pt 6):1015-8.

PMID:
1388940
31.

[History of dentistry of the ancient Hebrews and Phoenicians].

Peiffer K.

Zahnarztl Gesundheitsdienst. 1976 Oct 15;(4):6-8. German. No abstract available.

PMID:
802453
32.

[Dentistry in the dynasties of ancient Egypt].

Peiffer KH.

Zahnarztl Gesundheitsdienst. 1974 Nov;(6):8-9. German. No abstract available.

PMID:
4620817

Supplemental Content

Loading ...
Support Center